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The lymphatic vasculature is essential for the recirculation of extracellular fluid, fat absorption, and immune function and as a route
of tumor metastasis. The dissection of molecular mechanisms underlying lymphangiogenesis has been accelerated by the identification
of tissue-specific lymphatic endothelial markers and the study of congenital lymphedema syndromes. We report the results of genetic
analyses of a kindred inheriting a unique autosomal-recessive lymphedema-choanal atresia syndrome. These studies establish linkage
of the trait to chromosome 1q32-q41 and identify a loss-of-function mutation in PTPN14, which encodes a nonreceptor tyrosine
phosphatase. The causal role of PTPN14 deficiency was confirmed by the generation of amurine Ptpn14 gene trapmodel that manifested
lymphatic hyperplasia with lymphedema. Biochemical studies revealed a potential interaction between PTPN14 and the vascular
endothelial growth factor receptor 3 (VEGFR3), a receptor tyrosine kinase essential for lymphangiogenesis. These results suggest a unique
and conserved role for PTPN14 in the regulation of lymphatic development in mammals and a nonconserved role in choanal
development in humans.The lymphatic system is composed of a network of vessels
that serves as a unidirectional transport system for fluid,
cells, and macromolecules from the interstitial spaces
back into the central circulation. Perturbations in the
development, maintenance, or function in the lymphatic
vascular network can lead to lymphedema, a sustained
accumulation of interstitial fluid with secondary pa-
thology as a consequence of increased hydrodynamic
pressure and decreased perfusion in the affected areas.1
The progression of events that initiates and organizes
lymphangiogenesis remains elusive, in part due to a
paucity of lymphatic endothelial cell-specific markers until
relatively recently. In the past decade, the identification of
major lymphangiogenic growth factors and lymphatic
endothelial markers has contributed significantly to the
understanding of the molecular mechanisms of lymphan-
giogenesis.2 A number of genes whose functions are crucial
for progression through the different stages of lymphan-
giogenesis have been identified through animal models
or human studies of congenital lymphedema (recently
reviewed by Tammela and Alitalo3).
Mutation of VEGFR3 (MIM 136352) in humans causes
Milroy disease4–6 (MIM 153100), isolated lymphedema at
birth secondary to absent or hypoplastic subcutaneous
lymphatic vessels.7,8 Heterozygosity for inactivating muta-
tion of Vegfr3 also results in lymphatic vessel hypoplasia,
chylous ascites, and lymphedema in the spontaneously
occurring Chy mouse.9 The essential role of VEGFR3
signaling in lymphangiogenesis has been underscored by
the embryonic lethal phenotype of mice lacking the gene1Department of Genetics & Genomic Sciences, Mount Sinai School of Medici
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lymphatic development was arrested but lymphatic speci-
fication and blood vessel development were unaffected.9
In contrast, overexpression of Vegfc in transgenic mouse
keratinocytes resulted in hyperplasia of cutaneous
lymphatic vessels.10,11
Apart from disease associated with deficiency ofVEGFR3,
several syndromic forms of lymphedemahave been charac-
terized at the genetic level in humans. These include muta-
tion of the transcription factors FOXC2 (MIM 602402), in
lymphedema-distichiasis syndrome12 (LD [MIM 153400]);
SOX18 (MIM 601618), in hypotrichosis-lymphedema-
telangiectasia syndrome13 (MIM 607823); CCBE1 (MIM
612753), in Hennekam lymphangiectasia-lymphedema
syndrome14 (MIM 235510); and NEMO (MIM 300248), in
osteopetrosis lymphedema, anhidrotic ectodermal dys-
plasia, and immunodeficiency syndrome15 (MIM
300301). The molecular bases of other rare syndromes in
which lymphedema is a major feature, such as cholestasis-
lymphedema syndrome (MIM 214900), have not yet been
determined. In 1982, a multigenerational consanguineous
Middle Eastern kindred was described with autosomal-
recessive inheritance of bilateral posterior choanal atresia
(MIM 608911), high arched palate, and other develop-
mental abnormalities (hypoplastic nipples, pericardial effu-
sion, and pectus excavatum) in one of the individuals.16
This pedigree was reported again in 1991 after five out of
seven individuals affected with choanal atresia developed
hard, nonpitting, lower-extremity lymphedemawith onset
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Figure 1. Haplotype Analysis of Choanal Atresia-Lymphedema Pedigree
A consanguineous pedigree is shown in which affected individuals manifest choanal atresia, lymphedema, and pericardial effusion.
Individual V-26 was an infant at the time of evaluation and may have been too young to manifest lymphedema. Haplotype analysis
of the critical region for choanal atresia-lymphedema syndrome on chromosome 1q32-q41 is shown. Markers inherited in homozy-
gosity in affected individuals are boxed in gray. The telomeric boundary of the critical region is at marker D1S2891 and the centromeric
boundary is at marker D1S229.pedigree (Figure 1) in a linkage study approved by the
institutional review board of the Mount Sinai School of
Medicine. All individuals provided informed consent, and
the study was performed in accordance with both institu-
tional and national ethical guidelines.We collected periph-
eral blood for extraction of genomic DNA and generation
of Epstein-Barr virus (EBV)-transformed lymphoblastoid
cell lines. Initially, six affected pedigree members were
genotypedwith short tandem repeat polymorphicmarkers,
and when homozygosity was observed in at least four
subjects, their parents were genotyped for marker informa-
tiveness. Upon identifying a marker that was homozygous
in all affected individuals and completely informative in
their parents, all available members of the pedigree were
genotyped with flanking markers and the data were
analyzed with the homozygosity mapping program Map-
makerHomoz, as described previously.18 Significant linkage
was achieved with a peak multipoint LOD score of 7.01 to
an interval on chromosome 1q32-q41 (Figure S1a, available
online). Haplotypes across this interval were constructed
manually and validated with the Genehunter 2 program19
for individual nuclear families. Haplotype analysis definedThe Americana 13.2 cM critical region (Figure 1) that spanned approxi-
mately 8.6 Mb and contained 52 predicted genes (Fig-
ure S1b). Positional candidate geneswere screened by direct
sequencing of amplicons produced from either genomic
DNA or reverse-transcribed cDNA. PROX1 (MIM 601546),
a candidate gene of particular interest given its function
as amaster regulator of lymphangiogenesis,20 was excluded
after extensive sequence analysis of exonic and flanking
intronic regions with the use of primers designed from
public genomic sequence with the Primer3 application
(available upon request).21
Because none of the remaining positional candidates
were known to play a role in lymphangiogenesis, genes
with a high probability of regulating intracellular signaling
were prioritized for sequence analysis. Protein tyrosine
phosphatase (PTP) mutations have been associated with
lymphedema in the case of PTPN11 (MIM 176876) and
Noonan syndrome (MIM 163950). PTPN11 encodes SHP-2,
a PTP with an established role in relaying signals from
several receptor tyrosine kinases through the RAS-MAPK
signaling pathway.22 SHP-2 has been shown to interact
with VEGFR3, and RAS proteins have recently beenJournal of Human Genetics 87, 436–444, September 10, 2010 437
Figure 2. cDNA and Genomic Mutation Analysis of PTPN14
(A) Amplification products of PTPN14 cDNA (left) or genomic
DNA (right) are shown. Lymphoblastoid cell total RNA was used
to generate cDNA (Superscript II reverse transcriptase; Roche) as
template for generating RT-PCR products spanning PTPN14 exons
3–8 from WT (left lane 1), obligate heterozygous (left lane 2), and
homozygous affected individuals (left lane 3). The expected sizes
of the full-length and truncated amplicon lacking exon 7 are
shown at right. A 3.2 kb amplification product from genomic
DNA (right lane 1) contained a ~2 kb deletion evident in ampli-
cons derived from heterozygous (right lane 2) and homozygous
(right lane 3) individual DNA samples.
(B) The absence of exon 7 was confirmed in mutant cDNA tran-
scripts (top), and the boundaries of the genomic deletion (bottom)
were defined by sequence analysis.
(C) Structural features of PTPN14 include an N-terminal FERM
domain, a central poorly conserved linker region with proline-
rich SH3-like motifs and an acidic polyglutamate domain, and
a C-terminal phosphatase domain (top). The location of the
frameshift introduced by loss of exon 7 within the tripartite
FERM domain is indicated by the red arrow (bottom).demonstrated to regulate VEGFR3 expression modulating
lymphatic endothelium, suggesting a potential mecha-
nism for lymphedema in RAS signaling disorders.23
PTPN14 (MIM 603155), which encodes a nonreceptor
PTP known alternatively as Pez, PTPD2, or PTP36 in the
mouse,24–26 was thus an attractive candidate.
We screened PTPN14 by generating overlapping RT-PCR
amplicons from lymphoblastoid cell-derived cDNA
(HQ116786) (Figure S1c). Primer pairs used for the
PTPN14 mutational analysis and other experiments are
provided in Table S1. As shown for an amplicon spanning
exons 3–8 (Figure 2A, left), the mutant transcript was
truncated relative to the expected product size. Sequence
analysis of the truncated transcript revealed absence of
exon 7 (Figure 2B, top). Exon 7 failed to amplify from
genomic DNA (HQ116785) templates obtained from
affected individuals, suggesting a genomic deletion. This
hypothesis was confirmed by amplification and sequence
analysis of a long-range PCR product that spanned exons
6–8 (Figure 2A, right). A 2016 bp deletion (Figure 2B,
bottom) inherited in homozygosity in all affected individ-
uals, clearly demonstrating that the mutation segregated
with the disease. This deletion was not present in 222
control chromosomes of Arab (n ¼ 62) or mixed European
(n ¼ 160) origin. The sample size was adequate for detec-
tion of rare polymorphisms with over 80% power within
the general European population. There were no genomic
structural elements, such as flanking repetitive sequences,
that suggested an obvious mechanism for the deletion.
Analysis of the transcripts and expressed sequence tags
mapping to this locus did not reveal evidence for alterna-
tive coding transcripts in which the exon was excluded,
nor were any alternative splicing isoforms observed during
RT-PCR amplification of the transcript from wild-type
(WT) or mutant lymphoblastoid cells.
PTPN14 contains two conserved structural elements: an
amino terminal FERM domain (band 4.1-ezrin-radixin-
moesin family of adhesion molecules) and a carboxy
terminal PTP domain.25,26 The subcellular localization of
the protein is dependent on serum concentration and
cell density27 and is regulated through serine/threonine
phosphorylation.28 The mutant PTPN14 transcript was
predicted to encode a frameshifted sequence after residue
193 and a premature termination codon after residue 211
(S194fs212X), interrupting the FERM domain after the
second of three subdomains (Figure 2C). Efforts to express
a construct corresponding to the mutant protein tagged
with the FLAG epitope resulted in only a low level of
expression restricted to the insoluble fraction (not shown),
suggesting that the protein was likely to be unstable and
catalytically inactive.
Despite extensive efforts, we were not able to identify
any additional individuals with the choanal atresia/
lymphedema syndrome, precluding formal genetic proof
that the PTPN14 deletion caused the disease phenotype.
To overcome this limitation, we capitalized on the avail-
able high-throughput murine gene targeting resources to438 The American Journal of Human Genetics 87, 436–444, Septembgenerate a mouse model of PTPN14 deficiency (Figure 3A).
Two embryonic stem cell lines (XE198 and RRR484) in
which exon-trapping vectors were integrated within the
Ptpn14 gene were obtained from the International Gene
Trap Consortium.29 The trap vectors were located iner 10, 2010
Figure 3. A Mouse Gene Trap Model of
Ptpn14 Deficiency
(A) Diagram of the insertion of a gene trap
viral vector into the genomic interval
between exons 5 and 6 of Ptpn14. Primer
pairs F3-R1 and 78-79 were used to screen
for the WT and trap alleles, respectively.
The results of PCR assays using tail-cut
genomic DNA from WT (þ/þ), heterozy-
gous (/þ), or homozygous (/) trap
allele mice are shown below.
(B) Lymphedema in the upper and lower
extremities and periorbital region in adult
mice homozygous for the Ptpn14 trap
allele. Visible swelling of the dorsal fore-
limbs and/or hindlimbs and/or periorbital
area was evident in a subset of animals.
The distal extremities and periorbital
region of a WT animal are shown (top)
for comparison.introns 13 and 5, respectively, and were predicted to
interrupt the protein after residues 354 and 170. The latter
mutant interrupted the FERM domain, providing a good
model of the human mutation. Feeder-independent
embryonic stem cells were maintained in a pluripotential
state in culture medium containing leukocyte inhibitory
factor (500 U/ml) and grown on gelatinized culture
flasks as recommended. These clones were sequence
validated and used to generate chimeric founders. Germ-
line transmission was observed from three chimeric ani-
mals generated from RRR484 but not from XE198
chimeras. Genotyping was performed by screening tail-
cut DNA for the presence of the b-geo fusion gene and
for the loss of the WT amplicon flanking the gene trap
insertion site. The insertion site in intron 5 was mapped
precisely by sequencing of chimeric amplicons, including
the ends of the trap vector and the flanking mouse
genomic DNA. Mice homozygous for the trap allele grew
slower than littermate WT controls, but the difference in
weight became nonsignificant after six months of age
(Figure S2a). Histologic analysis of postnatal cranial
sections revealed no evidence of choanal atresia (Fig-
ure S2b), and morphologic evaluation of adult animal
facial structures did not reveal any overtly dysmorphic
features (Figure S2c). Lymphedema was not observed in
any animals at birth, but after 5 mo, approximately 14%
of themutant animals displayed forelimb and/or hindlimb
swelling or periorbital edema (Figure 3B).
Given the genetic evidence that PTPN14 plays a role in
lymphatic function, we then investigated the effect ofThe American Journal of Human GenetPTPN14 deficiency on lymphatic
vascular patterning. We performed
whole-mount immunohistochemistry
experiments to visualize the lym-
phatic capillaries in ears from symp-
tomatic Ptpn14trap/trap and WT mice.These studies revealed that the lymphatic capillaries were
hyperplastic in symptomatic mutant animals (Figure 4A),
a finding in striking contrast to the lymphatic hypoplasia
resulting from loss of VEGFR3 function.9 Of note, the
Foxc2-deficient mouse model of lymphedema-distichiasis
syndrome30 also manifests lymphatic hyperplasia. Work
in this model has revealed that Foxc2 andVegfr3 act cooper-
atively in lymphatic patterning, with Vegfr3 potentially
acting as an upstream regulator of Foxc2.31
Unlike the mouse model, the lymphedema phenotype
in the human disease was completely penetrant by late
childhood, raising the possibility that skipping of the
gene trap could produce WT transcript and ameliorate
the phenotype. Analysis of mRNA splicing with the use
of WT and mutant allele-specific oligonucleotides con-
firmed the presence ofWT transcripts inmice homozygous
for the trap allele but without a lymphatic phenotype,
consistent with leakiness of the trap (Figure 4B). This
phenomenon has previously been described for other
trap alleles.32,33 We assessed the transcript abundance of
the correctly spliced and gene-trapped isoforms in a set
of phenotypically normal trap homozygote and WT mice
using thymocyte-derived RNA (Figure 4C). Interestingly,
whereas the abundance of a reference gene transcript
(Gapdh) was relatively uniform across all samples (not
shown), the expression of the WT transcript was highly
variable. The trap isoform also showed variable levels of
expression but was present in all mutant samples. Of
note, the WT isoform was not observed in two trap homo-
zygotes. When peripheral blood leukocytes were used asics 87, 436–444, September 10, 2010 439
Figure 4. Lymphatic Hyperplasia in
Symptomatic Ptpn14 Mutant Mice
(A) Immunohistochemical staining of ear
skin sections from WT (top) and mutant
(bottom) mice. After treatment with Nair
for hair removal, ear leafletswere separated
and the central cartilage removed. The
epidermal layer was removed by treatment
with 0.5 M ammonium thiocyanate, and
dermal skin was fixed with 100% acetone
and 80% methanol before antibody incu-
bations. Lymphatic vessels were stained
with rabbit anti-LYVE1 (Upstate) followed
by anti-rabbit Alex Fluor 488 (Molecular
Probes), and blood vessels were visualized
with panendothelial rat anti-CD31 (BD
Biosciences) followed by anti-rat Alexa
Fluor 594 (Molecular Probes). Images
were captured with a Zeiss Axiophot2 fluo-
rescencemicroscope aftermounting (Dako
Cytomation). Immunostaining of the
lymphatic endothelial marker LYVE1
(green) and the vascular endothelial pre-
dominant marker CD31 (red) are shown
at low magnification (253). A higher-
magnification view (1003) of LYVE1 stain-
ing is shown at right. The sections from
mutant animals have an increased density
of LYVE1-positive lymphatic capillaries
compared to WT ear sections.
(B) Ear sections from symptomatic mutant
(left), WT (center), and nonsymptomatic
mutant (right)mice are shownwith confir-
matory genotyping (gDNA) and expres-
sion analysis (cDNA) for Ptpn14 WT and
trap alleles shown below. Genomic DNA
was obtained from tail cuts, and cDNA
was obtained from peripheral blood. The
Ptpn14 trap transcript was amplified with
primers specific for exon 5 and the b-geo
open reading frame.WT transcripts arising
by skipping of the trap exon were detected
with the use of primers flanking the exon
5–6 splice junction. WT transcripts were
readily detected with cDNA derived from
asymptomatic mice but not with that
from symptomatic mice.
(C) Real-time quantitative PCR with thymocyte-derived cDNA from WT and asymptomatic trapped animals for the calculation of
generated WT and trapped transcripts. 20 ng of cDNA and 0.2 mM of each primer (Table S1) with SYBR Green Master (Rox) (Roche)
were amplified in anABI PRISM7900HTdetection system for 40 cycles in triplicate. Transcript abundancewas calculatedwith the formula
25003 1.93^((mean Gapdh Ct)(mean transcript Ct)), with Ct as the threshold cycle. The right panel shows differential splicing of WT
transcripts in asymptomatic trapped animals in thymocyte- versus leukocyte-derived cDNA.WTand trap products from qPCR in the left
panel were analyzed by gel electrophoresis. Lanes: 1, negative control; 2, WT; 3–5, homozygous Ptpn14trap. Trap amplicons derived from
the thymuswerepresent inallmutant samplesbutnot in theWTsample (toppanel).WTampliconswerepresent inonlyone (lane5)of the
three mutant samples derived from the thymus (middle panel) but in all samples derived from blood (bottom panel).the RNA source, expression of the WT isoform was de-
tected, confirming that alternative splicing of the gene
trap exon was not uniform in different tissues (Figure 4C,
right panel). Because the trap allele is hypomorphic rather
than a true null, a role for PTPN14 in choanal development
in mice cannot be definitively excluded.
The expression pattern of PTPN14 is broad,26 including
breast, kidney, skeletal muscle, lung, placenta, heart, and
pancreas, and is not consistent with the observed lym-
phatic and choanal atresia phenotype, so we then sought
to confirm the physiologic relevance of PTPN14 to lym-
phangiogenesis. The robust expression of PTPN14 in440 The American Journal of Human Genetics 87, 436–444, Septembhuman umbilical vein endothelial cells (HUVECs) has
been proposed to suggest a potential role in endothelial
cell function.27 We carried out RT-PCR and immunoblot
analyses in lymphatic endothelial cells isolated from
human foreskin (generously provided by M. Skobe) and
established that PTPN14 was transcribed and translated
in these cells (Figure 5A), consistent with a potential role
for the gene in lymphatic endothelial development and/
or function.
The mechanism by which the protein could medi-
ate such an effect is unclear, because PTPN14 has a
dynamic subcellular localization pattern, with targetinger 10, 2010
Figure 5. PTPN14 CanModulate VEGFR3
Receptor Activation in a Specific Fashion
(A) cDNA and total protein lysates were
prepared from human foreskin lymphatic
endothelial cells (LECs) for RT-PCR and
immunoblot analyses. PTPN14 polyclonal
rabbit primary antisera (a generous gift
from Y. Khew-Goodall) were raised against
a peptide corresponding to PTPN14 resi-
dues 683–696 as described previously,
and subsequent aliquots were generated
against this same epitope in rabbits.
PTPN14 transcription (top) and protein
expression (bottom) were confirmed in
LECs, absent in HEK293 cells (), and
present in HEK293 cells expressing Flag-
tagged PTPN14 (þ).
(B) HEK293 cells were cotransfected with
combinations of V5-tagged VEGFR3, V5-
tagged EB1, and FLAG-tagged PTPN14 as
indicated at right. Confluent HEK293 cell
monolayers were washed with PBS on
ice and then scraped with lysis buffer
(20 mM Tris pH 7.6, 150 mMNaCl, 50 mM
NaF, 1 mM Na3VO4, 1 mM EDTA, 1% [v/v]
Triton X-100, 0.5% [w/v] sodium deoxy-
cholate, 0.1% [w/v] SDS) and protease
inhibitors (Complete Protease Inhibitor
Tablets, Roche). Lysates were immunoprecipitated with mouse anti-V5 antibody (Invitrogen), and coimmunoprecipitation of
FLAG-tagged PTPN14 (top row) was detected by immunoblotting with anti-PTPN14 antibody. Blots were stripped and reprobed with
anti-V5 antibody to confirm the immunoprecipitation of V5-tagged VEGFR3 (second row) and V5-tagged EB1 (third row). PTPN14 coim-
munoprecipitated with V5-tagged VEGFR3, but not with a control protein, V5-tagged EB1, under basal conditions in serum-replete
medium (lanes 3 and 4). Human recombinant vascular endothelial growth factor-C (VEGFC; R&D Systems) stimulation of transfected
cells resulted in a more robust interaction relative to serum-starved cells (lanes 5 and 6). Experiments were repeated three to five times,
and representative data are shown.to intercellular junctions in confluent, quiescent HUVECs
and nuclear translocation in proliferating cells.27 Given
the critical importance of VEGFR3 in lymphangiogenesis,
we tested the hypothesis that the phosphatase and the
VEGFR3 receptor might form a physical complex in cells
expressing both proteins. We coexpressed FLAG-tagged
PTPN14 (generously provided by Y. Khew-Goodall27) and
a full-length human VEGFR3 cloned into the pcDNA6-
V5-HisA expression vector. Coimmunoprecipitation of
FLAG-tagged PTPN14 was observed after immunoprecipi-
tation of V5-tagged VEGFR3, but not with the negative
control, V5-tagged EB1 (Figure 5B). The abundance of
coimmunoprecipitated PTPN14 was enhanced by stimula-
tion of transfected cells with VEGFC. These results were
consistent with the hypothesis that VEGFC-mediated
signaling may enhance the recruitment of PTPN14 to a
protein complex that includes VEGFR3. The potential of
these proteins to interact in vivo is also supported by
independent work demonstrating that the expression
patterns of Ptpn14 and Vegfr3 are broad and exhibit
substantial overlap.25,34 The notion that PTPN14 might
function in a multiprotein complex is further supported
by the established role of its closest relative, PTPN21
(MIM 603271), which regulates proliferative signaling
pathways through a scaffolding function.35,36 Two struc-
tural motifs in PTPN14, the FERM domain37 and a pro-
line-rich potential SH3 motif,25 could function as adaptors
in signal transduction.The AmericanThe mechanism by which PTPN14 functions in lym-
phatic development is still uncertain. The accumulation
of the protein at adherens junctions and its ability to
dephosphorylate b-catenin implicate PTPN14 in pro-
moting cell adhesion,38 conceivably by maintaining the
integrity of lymphatic capillaries. In this model, loss of
the protein leads to lymphatic dysfunction, capillary
leakage, and compensatory hypertrophy. However, in light
of the observed cytostatic effect of overexpression in 3T3
cells39 we have not ruled out the possibility that PTPN14
may function as a growth suppressor in lymphatic endo-
thelial cells, with hyperplasia as a consequence of loss of
function.
At present, we do not have evidence that PTPN14 plays
a role in other syndromic or nonsyndromic forms of lym-
phedema. We have not identified any other kindred with
recessively inherited choanal atresia and childhood-onset
lymphedema as primary phenotypic features, despite
extensive literature searching. Additionally, screening of
a collection of familial lymphedema pedigrees that did
not manifest choanal atresia with the markers used in
this pedigree did not identify any potentially linked
families (D. Finegold, R. Ferrell, personal communication).
Gorham disease (MIM 123880), which involves the over-
growth of lymphatic vessels into bones,40 is a disorder
with potential linkage to PTPN14 and/or VEGFR3 on the
basis of its pathophysiology. However, although pericar-
dial effusion is an overlapping phenotype betweenJournal of Human Genetics 87, 436–444, September 10, 2010 441
Gorham disease and choanal atresia-lymphedema
syndrome, the typical musculoskeletal pain or progressive
degenerative bone deformities were not present in the two
clinical reports describing the phenotype in the current
pedigree.
The role of PTPs in human disease has been a subject of
increasing interest, particularly with respect to cancer
development.41 PTEN (MIM 601728) is a well-character-
ized cause of multiple distinct hamartoma tumor
syndromes due to germline inactivating or deletion muta-
tions.42 More recently, germline gain-of-function (GOF)
mutations in PTPN11 have been shown to cause Noonan
and Leopard (MIM 151100) syndromes,43,44 with sporadic
GOF mutations detected in a subset of leukemias.45 With
regard to non-Mendelian disease, a functional SNP in
PTPN22 (MIM 600716) encoding a GOF variant (R620Y)
has been associated with a variety of autoimmune condi-
tions.46 To date, the only proposed role for PTPN14 in
human disease has been as a potential tumor suppressor,
on the basis of the presence of sporadic mutations in
colorectal cancer cells.47 The phenotype of the family
under study does not include early-onset cancer. Rather,
our findings identify PTPN14 as a unique regulator of
lymphatic development in mammals and choanal devel-
opment in humans. Future studies will be necessary to
elucidate the molecular mechanisms by which the protein
exerts its in vivo biological effects.Supplemental Data
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